SCHEMBL2056296

SCHEMBL2056296

Cc1c[nH]c(-c2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.43
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NISCH Q9Y2I1 1/20 0.42
GRK6 P43250 1/20 0.41
SCN5A Q14524 3/20 0.41
SCN10A Q9Y5Y9 6/20 0.40
KCNH2 Q12809 3/20 0.40
SCN1A P35498 1/20 0.40
SCN9A Q15858 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN8A Q9UQD0 1/20 0.40
TDP2 O95551 1/20 0.40
NOTUM Q6P988 1/20 0.40
WNT3A P56704 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
CHRNA7 P36544 1/20 0.39
KIF11 P52732 1/20 0.39
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27985279 0.80 MAPK1 (0.40) NISCHTNKS2
SCHEMBL10553981 0.80 KDM4E (0.50) SCN2ATNKS2
SCHEMBL15293725 0.78 KDM4E (0.49) TNKS2
SCHEMBL15330754 0.77 GRK6 (0.41) TRPV1POLBL3MBTL1NISCHGRK6
SCHEMBL26096161 0.77 GRK6 (0.39) TRPV1NISCHGRK6SCN5ASCN10A
SCHEMBL15967361 0.76 GRK6 (0.49) GRK6SCN9A
SCHEMBL26464281 0.76 TRPV1 (0.41) TRPV1NISCHGRK6SCN5ASCN10A
SCHEMBL3401143 0.76 CCNT1 (0.43) TRPV1L3MBTL1NISCHGRK6SCN5A
SCHEMBL26464150 0.76 ALOX5 (0.50) L3MBTL1NISCHGRK6SCN5ACHRNA7
SCHEMBL28279252 0.75 ALDH1A1 (0.46) POLBTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 TRPV1 2567/4885POLB 757/4885L3MBTL1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.